微信公众号

请长按图片识别二维码

模型资源

首页 模型资源 细胞资源 CT26-Pd‑l1 KO

Design of the CT26-Pd‑l1 Knockout

The CT26.WT cell line was derived and subcloned from Balb/c murine colon carcinoma and forms tumors at high frequency when inoculated subcutaneously. We generated CT26-Pd-l1 Knockout clonal cell lines invalidated for murine Pd-l1 (Cd274).

‍

Applications in immuno-oncology

The CT26-Pd-l1 Knockout clones can be used for target validation and mechanistic studies.

Humanized CT26-hPD-L1 cell line:
Use our humanized CT26-hPD-L1 cell line for in vivo tumor growth assays in syngeneic models.

‍

CT26-Pd-l1 Knockout features

  • Invalidated for murine Pd-l1
  • Form tumors upon subcutaneous injection in fully immunocompetent mice

  • Invalidation of murine Pd-l1 in CT26-Pd-l1 Knockout cells

    Expression analysis by FACS. mPd-l1 expression in CT26‑Pd‑l1 Knockout (KO) clone and parental cell line.

     

  • CT26-Pd-l1 KO cells form tumors in vivo

    Wild-type Balb/c mice were injected (s.c.) with 1x105 CT26.WT (A) or CT26-Pd-l1 KO (B) cells. Tumor growth was measured every 2 to 3 days. Tumor size (mm3) = (width2 x length)/2. 8 mice (mixed gender) were injected per group, with 8 mice developing tumors for CT26.WT and CT26-Pd-l1 KO.

     

     

     

更多详细数据请联系我们：联系我们 - 基锘威 - genOway (my3w.com)

Commentaries

  1. Development of a new hSIRPα-specific radiotracer for non-invasive PET imaging using genOway’s double humanized hCD47/hSIRPα mouse and MC38-hPD-L1-hCD47-LZ cell line
  2. CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity
  3. A new promising family of small molecules regulating the PD-L1/PD-1 signaling pathway
  4. Improving in vitro models: the coming of age of organoids
  5. iPS technology: Four factors that will change the world… some day

Scientific articles

  1. Two birds with one stone: human SIRPα nanobodies for functional modulation and in vivo imaging of myeloid cells
  2. CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity
  3. ERα-36 regulates progesterone receptor activity in breast cancer
  4. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer
  5. Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
  6. SDHA gain-of-function engages inflammatory mitochondrial retrograde signaling via KEAP1-Nrf2